<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03486067</url>
  </required_header>
  <id_info>
    <org_study_id>CC-93269-MM-001</org_study_id>
    <secondary_id>U1111-1210-6325</secondary_id>
    <secondary_id>2017-003448-19</secondary_id>
    <nct_id>NCT03486067</nct_id>
  </id_info>
  <brief_title>Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Subjects With Relapsed and Refractory Multiple Myeloma</brief_title>
  <official_title>A Phase 1, Open-label, Dose Finding Study of CC-93269, a BCMA X CD3 T Cell Engaging Antibody, in Subjects With Relapsed and Refractory Multiple Myeloma.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celgene</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Celgene</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study CC-93269-MM-001 is an open-label, Phase 1, dose escalation (Part A and C) and expansion&#xD;
      (Parts B and D), first-in-human clinical study of CC-93269 in subjects with relapsed and&#xD;
      refractory multiple myeloma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The dose escalation parts (Part A with CC-93269 administered intravenous (IV) and Part C&#xD;
      subcutaneous (SC)) of the study will evaluate the safety and tolerability of escalating doses&#xD;
      of CC-93269, administered IV or SC, to determine the maximum tolerated dose (MTD) and&#xD;
      non-tolerated dose (NTD) of CC-93269. The expansion parts (Part B and D) will further&#xD;
      evaluate the safety and efficacy of CC-93269 administered IV or SC at or below the MTD in&#xD;
      selected expansion cohorts of up to approximately 20 evaluable subjects each in order to&#xD;
      determine the Recommended Phase 2 dose (RP2D).One or more dosing regimens may be selected for&#xD;
      cohort expansion. All treatments will be administered in 28-day cycles for up to 2 years or&#xD;
      extended up to 5 years for subjects maintaining clinical benefit at the discretion of the&#xD;
      Safety Review Committee, until confirmed disease progression, unacceptable toxicity, or&#xD;
      subject/investigator decision to withdraw.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 3, 2018</start_date>
  <completion_date type="Anticipated">November 30, 2026</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2026</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events (AEs)</measure>
    <time_frame>Up to 48 months</time_frame>
    <description>Number of participants with Adverse Events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose Limiting Toxicity (DLT)</measure>
    <time_frame>Up to 48 months</time_frame>
    <description>Is defined as any of the toxicities occurring within the DLT assessment window (Cycle 1, Days 1 to 28) except those that are clearly and incontrovertibly due to extraneous causes.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Non-Tolerated Dose (NTD)</measure>
    <time_frame>Up to 48 months</time_frame>
    <description>Is defined as a dose level at which 2 or more of up to 6 evaluable subjects in any dose cohort experience a DLT in the DLT window.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD)</measure>
    <time_frame>Up to 48 months</time_frame>
    <description>Is defined as the last dose cohort below the NTD with 0 or 1 out of 6 evaluable subjects experiencing a DLT during the DLT window.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>Up to 48 months</time_frame>
    <description>Is defined as the proportion of subjects who achieve a partial response or better (eg, PR, VGPR, CR or sCR), according to International Myeloma Working Group (IMWG) response criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Response</measure>
    <time_frame>Up to 48 months</time_frame>
    <description>Is defined as the time from the first CC-93269 dose date to the date of first documented response (PR or better).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>Up to 48 months</time_frame>
    <description>Is defined as the time from the earliest date of documented response (≥ PR) to the first documented disease progression or death, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>Up to 48 months</time_frame>
    <description>Is defined as the time from the first dose of CC-93269 to progressive disease or death from any cause, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Up to 48 months</time_frame>
    <description>Is defined as the time from the first dose of CC-93269 to death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - Cmax</measure>
    <time_frame>Up to 48 months</time_frame>
    <description>Maximum serum concentration of drug</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - Cmin</measure>
    <time_frame>Up to 48 months</time_frame>
    <description>Minimum serum concentration of drug</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - AUC</measure>
    <time_frame>Up to 48 months</time_frame>
    <description>Area under the curve</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - tmax</measure>
    <time_frame>Up to 48 months</time_frame>
    <description>Time to peak (maximum) serum concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - t1/2</measure>
    <time_frame>Up to 48 months</time_frame>
    <description>Terminal Half-life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - CL</measure>
    <time_frame>Up to 48 months</time_frame>
    <description>Apparent total body clearance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - Vss</measure>
    <time_frame>Up to 48 months</time_frame>
    <description>Volume of distribution at steady-state</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - accumulation index of CC-93269</measure>
    <time_frame>Up to 48 months</time_frame>
    <description>Accumulation ratio of drug</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence and frequency of anti-drug antibodies (ADA)</measure>
    <time_frame>Up to 48 months</time_frame>
    <description>Detection of anti-drug antibodies in participants and frequency of anti-drug antibodies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate measures of tumor sensitivity/ resistance to CC-93269</measure>
    <time_frame>Up to 48 months</time_frame>
    <description>Measurement of tumor and immune factors</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">175</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Administration of CC-93269</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CC-93269 will be administered to each patient on a 28-day cycle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CC-93269</intervention_name>
    <description>CC-93269</description>
    <arm_group_label>Administration of CC-93269</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Subjects must satisfy the following criteria to be enrolled in the study:&#xD;
&#xD;
          1. Subject must understand and voluntarily sign an informed consent form (ICF) prior to&#xD;
             any study-related assessments/procedures being conducted.&#xD;
&#xD;
          2. Subject (male or female) is ≥ 18 years of age the time of signing the ICF.&#xD;
&#xD;
          3. Subject has non-secretory multiple myeloma, plasma cell leukemia, Waldenstrom's&#xD;
             macroglobulinemia, POEMS (polyneuropathy, organomegaly, endocrinopathy, monoclonal&#xD;
             protein, and skin changes) syndrome, or amyloidosis.&#xD;
&#xD;
          4. Subjects must have measurable disease (as determined by the central lab).&#xD;
&#xD;
          5. Subject consents to hospitalization for monitoring and collection of study peripheral&#xD;
             blood samples.&#xD;
&#xD;
          6. Subject consents to serial bone marrow aspirations and/or biopsies during Screening,&#xD;
             study treatment and at the end of treatment.&#xD;
&#xD;
          7. Subject has an Eastern Cooperative Oncology Group (ECOG) PS of 0 or 1.&#xD;
&#xD;
          8. Subjects must have adequate hematologic, liver, renal, and coagulation function as&#xD;
             assessed by laboratory tests.&#xD;
&#xD;
          9. Females and males must practice true abstinence or agree to contraceptive methods&#xD;
             throughout the study, and during the safety follow-up period.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        The presence of any of the following will exclude a subject from enrollment:&#xD;
&#xD;
          1. Subject has received prior therapy directed at B cell maturation antigen (BCMA).&#xD;
&#xD;
          2. Subject has symptomatic central nervous system involvement of multiple myeloma.&#xD;
&#xD;
          3. Subject has non-secretory multiple myeloma, plasma cell leukemia, Waldenstrom's&#xD;
             macroglobulinemia, POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy,&#xD;
             monoclonal protein, and skin changes), or amyloidosis.&#xD;
&#xD;
          4. Subject is on chronic systemic immunosuppressive therapy or corticosteroids.&#xD;
&#xD;
          5. Subjects with clinically significant cardiac disease.&#xD;
&#xD;
          6. Subject had a prior autologous stem cell transplant ≤ 3 month prior to starting&#xD;
             CC-93269.&#xD;
&#xD;
          7. Subject had a prior allogeneic stem cell transplant ≤ 12 month prior to starting&#xD;
             CC-93269.&#xD;
&#xD;
          8. Subject had a prior systemic cancer-directed treatments or investigational modalities&#xD;
             ≤ 5 half-lives or 4 weeks prior to starting CC-93269, whichever is shorter. Subjects&#xD;
             must have recovered from any clinically significant non-hematologic toxicities (ie, to&#xD;
             Grade ≤1) of prior systemic anti-cancer directed treatments unless otherwise specified&#xD;
&#xD;
          9. Subject had major surgery ≤ 2 weeks prior to starting CC-93269.&#xD;
&#xD;
         10. Subject is a pregnant or lactating female.&#xD;
&#xD;
         11. Subject has known history or serologic evidence of human immunodeficiency virus (HIV)&#xD;
             infection.&#xD;
&#xD;
         12. Subject has known history, virologic or serological evidence of hepatitis B or C virus&#xD;
             (HBV/HCV) infection. Subjects who had HCV but have received an antiviral treatment and&#xD;
             show no detectable HCV viral RNA for 6 months are eligible&#xD;
&#xD;
         13. Subject has a history of a venous thromboembolic event (VTE) within 6 months prior to&#xD;
             study entry (eg, deep-vein thrombosis or pulmonary embolism). Subjects with distant&#xD;
             history of VTE (ie, occurring &gt; 6 months prior to study entry) who require ongoing&#xD;
             treatment with chronic, therapeutic dosing of anti-coagulants (eg, warfarin, low&#xD;
             molecular weight heparin, Factor Xa inhibitors) are eligible for study entry.&#xD;
&#xD;
         14. Subject has a history of concurrent second cancers requiring active, ongoing systemic&#xD;
             treatment.&#xD;
&#xD;
         15. Subject has a history or presence of clinically relevant central nervous system (CNS)&#xD;
             pathology.&#xD;
&#xD;
         16. Subject has any significant medical condition, laboratory abnormality, or psychiatric&#xD;
             illness that would prevent the subject from participating in the study.&#xD;
&#xD;
         17. Subject has any condition (eg, active or uncontrolled infection) including the&#xD;
             presence of laboratory abnormalities, which places the subject at unacceptable risk if&#xD;
             he/she were to participate in the study. .&#xD;
&#xD;
         18. Subject has any condition that confounds the ability to interpret data from the study.&#xD;
&#xD;
         19. Subject has inadequate pulmonary function.&#xD;
&#xD;
         20. Subject has active, uncontrolled, or suspected infection.&#xD;
&#xD;
         21. Subject has pulmonary, cardiac, or hepatic involvement of extramedullary multiple&#xD;
             myeloma.&#xD;
&#xD;
         22. Subjects with a history of severe allergic or anaphylactic reactions or&#xD;
             hypersensitivity to excipients in the investigational product.&#xD;
&#xD;
         23. Recent SARS-CoV-2 vaccine as specified in the protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael R Burgess, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Celgene</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Associate Director Clinical Trial Disclosure</last_name>
    <phone>1-888-260-1599</phone>
    <email>clinicaltrialdisclosure@bms.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of California San Francisco Medical Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94142</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Yale Cancer Center</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Winship Cancer Institute of Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Henry Ford Medical Center - New Center One</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai Mount Sinai West</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10019</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Swedish Cancer Institute</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinik Hamburg - Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Papa Giovanni XXIII</name>
      <address>
        <city>Bergamo</city>
        <zip>24127</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Istituto Scientifico Romagnolo Per Lo Studio e La Cura Dei Tumori (I.R.S.T.)</name>
      <address>
        <city>Meldola</city>
        <zip>47014</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Istituto Clinico Humanitas</name>
      <address>
        <city>Milan</city>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Vall d´Hebron University Hospital</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Germans Trias i Pujol ICO Badalona</name>
      <address>
        <city>Barcelona</city>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital General Gregorio Maranon</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinica Universidad de Navarra</name>
      <address>
        <city>Pamplona</city>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universtario Marques de Valdecilla</name>
      <address>
        <city>Santander</city>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital de la Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Doctor Peset</name>
      <address>
        <city>Valencia</city>
        <zip>46017</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sahlgrenska University Hospital</name>
      <address>
        <city>Gothenborg</city>
        <zip>413 46</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Skanes Universitetssjukhus Lund</name>
      <address>
        <city>Lund</city>
        <zip>SE-221 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Karolinska Universitetssjukhuset - Solna</name>
      <address>
        <city>Solna</city>
        <zip>171 76</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>March 21, 2018</study_first_submitted>
  <study_first_submitted_qc>March 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 3, 2018</study_first_posted>
  <last_update_submitted>October 5, 2021</last_update_submitted>
  <last_update_submitted_qc>October 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiple Myeloma</keyword>
  <keyword>BCMA X CD3 T Cell</keyword>
  <keyword>Antibody</keyword>
  <keyword>CC-93269</keyword>
  <keyword>Relapsed and Refractory</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

